Aradigm offers an end‑to‑end financial and delivery platform for cell and gene therapies that standardizes pricing, manages reimbursement, and coordinates care across payers, providers, manufacturers, and patients.
Funding
Funding not disclosed
Founders
Product
Problem
Cell and gene therapies offer curative potential but have extremely high and variable costs, creating financial risk for providers and insurers and limiting patient access. The lack of a coordinated delivery and payment infrastructure leads to cash‑flow challenges, pricing uncertainty, and administrative complexity across the care pathway.
Solution
Aradigm provides an end‑to‑end financial and delivery platform that standardizes pricing, manages reimbursement, and coordinates care for cell and gene therapies. The platform offers transparent, predictable pricing contracts that reduce price variation of up to 242% between providers. It integrates with payers, providers, manufacturers, and patients to streamline authorization, financing, and logistics, delivering a concierge‑level patient experience while protecting provider cash flow. By aggregating demand and applying risk‑adjusted financing, Aradigm helps insurers bend the cost curve and ensures eligible patients receive approved therapies. The solution also supplies analytics and reporting tools to monitor utilization, outcomes, and cost trends across the therapy lifecycle.
Target Audience
Primary customers are health insurers, employer health plans, and large provider networks that deliver cell and gene therapies, as well as therapy manufacturers seeking streamlined market access.
Features
- Fixed‑price contracts with transparent, predictable cost structures for each therapy
- Integrated care coordination that aligns payer authorization, provider scheduling, and manufacturer supply chain
- Risk‑adjusted financing and cash‑flow protection mechanisms for providers
- Concierge‑style patient navigation and support throughout the treatment journey
- Real‑time analytics dashboard for payers and providers to track utilization, outcomes, and cost metrics
- Scalable platform architecture that supports multiple cell and gene therapy indications and manufacturers